{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:14:11Z","timestamp":1792790051199,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health with Current Research funds"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Chronic migraine (CM) in childhood and adolescence is associated with a high disease burden, including impaired quality of life, school absenteeism, and reduced daily functioning. OnabotulinumtoxinA (ONA) is approved for prophylactic treatment of CM in adults, but its use in pediatric patients remains off-label, with evidence still limited. This narrative review summarizes current data on the efficacy, safety, and tolerability of ONA in pediatric CM, drawing from randomized controlled trials, prospective cohorts, and retrospective series. In addition to summarizing efficacy and safety data, our review aims to focus on potential practical clinical implications and on discussion points and research questions that remain open.<\/jats:p>","DOI":"10.3390\/toxins17100476","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:05:13Z","timestamp":1758801913000},"page":"476","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Onabotulinumtoxin-A for Chronic Migraine in Children and Adolescents: A Narrative Review of Current Evidence and Clinical Perspectives"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3336-9205","authenticated-orcid":false,"given":"Laura","family":"Papetti","sequence":"first","affiliation":[{"name":"Developmental Neurology Unit, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Piazza di Sant\u2019Onofrio 4, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[{"name":"School of Health, Unitelma Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-103X","authenticated-orcid":false,"given":"Massimiliano","family":"Valeriani","sequence":"additional","affiliation":[{"name":"Developmental Neurology Unit, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Piazza di Sant\u2019Onofrio 4, 00165 Rome, Italy"},{"name":"Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University of Rome, 00133 Rome, Italy"},{"name":"Translational Pain Neuroscience and Precision Medicine, CNAP, Department of Health Science and Technology, School of Medicine, Aalborg University, 9260 Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s10194-024-01889-x","article-title":"Hallmarks of primary headache: Part 1\u2014Migraine","volume":"25","author":"Raggi","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s10194-023-01541-0","article-title":"European Headache Federation School of Advanced Studies (EHF-SAS). Primary headache epidemiology in children and adolescents: A systematic review and meta-analysis","volume":"24","author":"Onofri","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/0333102416660533","article-title":"Diagnosis of primary headache in children younger than 6 years: A clinical challenge","volume":"37","author":"Torriero","year":"2017","journal-title":"Cephalalgia"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Papetti, L., Salfa, I., Battan, B., Moavero, R., Termine, C., Bartoli, B., Di Nunzio, F., Tarantino, S., Alaimo Di Loro, P., and Vigevano, F. (2019). Features of Primary Chronic Headache in Children and Adolescents and Validity of Ichd 3 Criteria. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00092"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-024-01766-7","article-title":"Unsatisfactory response to acute medications does not affect the medication overuse headache development in pediatric chronic migraine","volume":"25","author":"Frattale","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tarantino, S., Proietti Checchi, M., Papetti, L., Ursitti, F., Sforza, G., Ferilli, M.A.N., Moavero, R., Monte, G., Capitello, T.G., and Vigevano, F. (2022). Interictal Cognitive Performance in Children and Adolescents With Primary Headache: A Narrative Review. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.898626"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Papetti, L., Ursitti, F., Moavero, R., Ferilli, M.A.N., Sforza, G., Tarantino, S., Vigevano, F., and Valeriani, M. (2019). Prophylactic Treatment of Pediatric Migraine: Is There Anything New in the Last Decade?. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00771"},{"key":"ref_9","unstructured":"US Food and Drug Administration (FDA) (2014). TOPAMAX\u00ae (topiramate) Tablets and Sprinkle Capsules, for Oral Use: Prescribing Information, Available online: https:\/\/www.fda.gov\/media\/100137\/download."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00431-025-06199-1","article-title":"Pediatric migraine care: Bridging gaps, overcoming barriers, and advancing solutions","volume":"184","author":"Peres","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s10194-024-01753-y","article-title":"CGRP-targeted medication in chronic migraine\u2014Systematic review","volume":"25","author":"Oliveira","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/head.14798","article-title":"The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta-analysis","volume":"64","author":"Lindsay","year":"2024","journal-title":"Headache"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinAfor treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"PREEMPT 2 Chronic Migraine Study Group Collaborators. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/rapm-2020-101605","article-title":"Effectivenessof onabotulinumtoxinA (BOTOX) in pediatric patients experienc-ing migraines: A randomized, double- blinded, placebo-controlledcrossover study in the pediatric pain population","volume":"46","author":"Shah","year":"2021","journal-title":"Reg. Anesth. Pain Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/head.13754","article-title":"A randomized trial to evaluate onabotulinumtoxinA for preven-tion of headaches in adolescents with chronic migraine","volume":"60","author":"Winner","year":"2020","journal-title":"Headache"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mavridi, A., Redmond, A., Archontakis-Barakakis, P., Bogdanova-Mihaylova, P., Deligianni, C.I., Mitsikostas, D.D., and Mavridis, T. (2024). Onabotulinumtoxina in the prevention of migraine in pediatric population: A systematic review. Toxins, 16.","DOI":"10.3390\/toxins16070295"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Dab\u00f3, L., Caronna, E., Mas-de-Les-Valls, R., Gallardo, V.J., Alpuente, A., Torres-Ferrus, M., and Pozo-Rosich, P. (2024). Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine. Toxins, 16.","DOI":"10.3390\/toxins16050221"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Papetti, L., Frattale, I., Ursitti, F., Sforza, G., Monte, G., Ferilli, M.A.D., Tarantino, S., Proietti Checchi, M., and Valeriani, M. (2023). Real life data on onabotulinumtoxinA for treatment of chronic migraine in pediatric age. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051802"},{"key":"ref_22","first-page":"151","article-title":"Experience of Botulinum Toxin A Injections for Chronic Migraine Headaches in a Pediatric Chronic Pain Clinic","volume":"26","author":"Santana","year":"2021","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pediatrneurol.2023.07.005","article-title":"Botulinum Toxin for Pediatric Migraine: A Retrospective Multisite Cohort Study","volume":"147","author":"Horvat","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.pmn.2023.04.006","article-title":"OnabotulinumtoxinA for pediatric migraine","volume":"24","author":"Karian","year":"2023","journal-title":"Pain Manag. Nurs."},{"key":"ref_25","first-page":"e4343","article-title":"Further evidence that onabotulinum toxin is a viable treatment option for pediatric chronic migraine patients","volume":"11","author":"Ali","year":"2019","journal-title":"Cureus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/08830738241227061","article-title":"The Use of Botulinum Toxin Type A in Medically Refractory Pediatric Patients With Chronic Daily Headaches and Its Impact on the Quality of Life","volume":"39","author":"Akbar","year":"2024","journal-title":"J. Child Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1055\/a-1832-9168","article-title":"Is Botox Right for Me: When to Assess the Efficacy of the Botox Injection for Chronic Migraine in Pediatric Population","volume":"53","author":"Goenka","year":"2022","journal-title":"Neuropediatrics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2022.02.002","article-title":"Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine","volume":"130","author":"Goenka","year":"2022","journal-title":"Pediatr. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0032-1329612","article-title":"Ten-year follow-up in a case series of integrative botulinum toxin intervention in adolescents with chronic daily headache and associated muscle pain","volume":"43","author":"Schroeder","year":"2012","journal-title":"Neuropediatrics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JNN.0b013e3181aaa98f","article-title":"Botox treatment for migraine and chronic daily headache in adolescents","volume":"41","author":"Chan","year":"2009","journal-title":"J. Neurosci. Nurs."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pediatrneurol.2010.06.001","article-title":"Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache","volume":"43","author":"Ahmed","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1177\/0883073818776142","article-title":"Onabotulinumtoxin A (BOTOX\u00ae) for prophylactic treatment of pediatric migraine: A retrospective longitudinal analysis","volume":"33","author":"Shah","year":"2018","journal-title":"J. Child Neurol."},{"key":"ref_33","unstructured":"U.S. Food and Drug Administration BOTOX\u00ae (OnabotulinumtoxinA) Prescribing Information. Silver Spring, MD: FDA; Revised 2011, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5236lbl.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11910-012-0251-1","article-title":"OnabotulinumtoxinA in pediatric chronic daily headache","volume":"12","author":"Kabbouche","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/0883073820931256","article-title":"The Efficacy of Botulinum Toxin in Pediatric Chronic Migraine: A Literature Review","volume":"35","author":"Marcelo","year":"2020","journal-title":"J. Child Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s10194-024-01819-x","article-title":"Children and adolescents with primary headaches exhibit altered sensory profiles\u2014A multi-modal investigation","volume":"25","author":"Pieniak","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s10194-024-01713-6","article-title":"Validity and reliability of Arabic version of pediatric migraine disability assessment scale (Child Self-Report versus Parent Proxy-Report): A multi-center study","volume":"25","author":"Magdy","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_38","unstructured":"European Medicines Agency (2022). Botox: EPAR\u2014Product Information, EPAR. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/botulinum-toxin-cmdh-scientific-conclusions-and-grounds-variation-amendments-product-information-and-timetable-implementation-psusa00000426202112_en.pdf."},{"key":"ref_39","first-page":"469","article-title":"Efficacy and safety of onabotulinumtoxinA with standardized occupational therapy for treatment of pediatric upper limb spasticity: Phase III placebo-controlled randomized trial","volume":"49","author":"Dimitrova","year":"2021","journal-title":"NeuroRehabilitation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000012573","article-title":"Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI","volume":"97","author":"Berweck","year":"2021","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41582-024-01002-5","article-title":"Insights from 25\u2009years of onabotulinumtoxinA in migraine\u2014Mechanisms and management","volume":"20","author":"Alpuente","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxinA in chronic migraine: A consensus statement from the European Headache Federation","volume":"19","author":"Bendtsen","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.bjps.2009.07.045","article-title":"Botulinum toxin injection pain relief using a topical anesthetic skin refrigerant","volume":"63","author":"Engel","year":"2010","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1111\/ene.14331","article-title":"Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: The PREVENBOX study","volume":"27","author":"Alpuente","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/0333102415621294","article-title":"Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database","volume":"36","author":"Hepp","year":"2016","journal-title":"Cephalalgia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ene.13523","article-title":"OnabotulinumtoxinA in chronic migraine: Predictors of response. A prospective multicentre descriptive study","volume":"25","author":"Santos","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Tarantino, S., Papetti, L., Di Stefano, A., Messina, V., Ursitti, F., Ferilli, M.A.N., Sforza, S., Moavero, R., Vigevano, F., and Gentile, S. (2020). Anxiety, Depression, and Body Weight in Children and Adolescents with Migraine. Front. Psychol., 11.","DOI":"10.3389\/fpsyg.2020.530911"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Moavero, R., Stornelli, M., Papetti, L., Ursitti, F., Ferilli, M.A.N., Balestri, M., Sforza, G., Tarantino, S., Vigevano, F., and Valeriani, M. (2020). Medication Overuse Withdrawal in Children and Adolescents Does Not Always Improve Headache: A Cross-Sectional Study. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00823"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1186\/s40064-015-1636-9","article-title":"OnabotulinumtoxinA 155 U in medication overuse headache: A two years prospective study","volume":"30","author":"Negro","year":"2015","journal-title":"Springerplus"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0021-9681(62)90048-6","article-title":"An analysis of the placebo phenomenon","volume":"15","author":"Liberman","year":"1962","journal-title":"J. Chronic Dis."},{"key":"ref_51","first-page":"3331024231178239","article-title":"Guidelines Update: Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition\u2014An experience-based update","volume":"43","author":"Hershey","year":"2023","journal-title":"Cephalalgia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/10\/476\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:49:29Z","timestamp":1760035769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/10\/476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["toxins17100476"],"URL":"https:\/\/doi.org\/10.3390\/toxins17100476","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}